Dr Wenzhi Tian is the founder and Chairman of ImmuneOnco Biopharma Co., Ltd, a start-up company in China, with primary focus of its R&D on tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANKTM) products that will meet the unmet medical needs both in China and global market.
Dr. Tian founded ImmuneOnco Biopharma in June of 2015 in Zhangjiang Hi-Tech Park dedicating to research and development of tumor immunotherapeutic drugs. Since the operation, Dr. Tian has built up a solid pipeline including several bi-specific recombinant proteins. The first project (IMM01) targeting CD47 is currently in preparation for clinical study.
Dr. Tian returned back to China in April of 2011 from ImClone Systems and established Huabo Biopharm Co., Ltd where he worked as Chief Executive Officer until April of 2015. While working at Huabo Biopharm, Dr. Tian filed three patent applications of which two had been granted (Patent numer: CN201110178342； CN201310283328.4). One of the granted patent (CN201310283328.4) has been developed for two IND filing in 2015 (CXSL1500123) and 2016 (CXSL1600135) respectively, and now all in clinical investigation.